GPT Healthcare Q2 Results 2026: PAT ₹15 Cr +36%, Revenue ₹136 Cr
Q2 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹136Cr
- +14.3% YoY
- +7.9% QoQ
- Net profit
- ₹15Cr
- +36.4% YoY
- +15.4% QoQ
- Margin
- 20%
- +1 pp YoY
- +1 pp QoQ
Guidance rank: #32 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
What the Q2 FY27 call signalled
2 of 4 strong
The short version
Revenue from operations grew 14.1% YoY in Q2 FY27 to INR135.6 crores; H1 FY27 revenue up 15.8% YoY to INR261.8 crores, indicating sustained growth. GPT Healthcare expects around 15%-16% revenue growth in FY27 over the previous year.
From GPT Healthcare Ltd's Q2 FY27 earnings-call transcript · updated 14 Nov 2026.
How did GPT Healthcare's revenue grow in the September 2026 quarter?
- Revenue from operations grew 14.1% YoY in Q2 FY27 to INR135.6 crores; H1 FY27 revenue up 15.8% YoY to INR261.8 crores, indicating sustained growth.
- Network inpatient volumes increased by approximately 11% in the quarter, boosting occupancy and revenues.
- Occupancy rates improved network-wide: 50.3% in Q2 FY27 (vs 47.4% previous year); mature hospitals excluding Raipur at 59.8%.
- Mature hospitals targeting optimal occupancy around 70%+ (e.g., Agartala aims for 70% occupancy soon).
- Newer hospitals like Raipur expected to break even by Q1 FY28 as occupancy rises (target ~35% occupancy).
- Expect continued growth driven by increased patient throughput, higher ARPOB, specialty mix enhancements, and expanded high-end clinical services.
2 more points from GPT Healthcare Ltd's call on revenue
Create a free account to keep reading this call
What happened to GPT Healthcare's margins in Q2 FY27?
See what GPT Healthcare Ltd said on profitability & margins — free account, 30 seconds.
What capex is GPT Healthcare planning?
- GPT Healthcare is commissioning a new 155-bed tertiary care hospital in Jamshedpur expected to commence operations in March-April 2027.
- The company is actively scouting and evaluating both greenfield and acquisition opportunities in Eastern India for expansion but aims only for meaningful contributors to top and bottom line.
- Management plans to add hospitals every couple of years to the overall portfolio, with ongoing expansion intent.
- There is scope for brownfield bed additions of up to 100 beds each at Agartala and Raipur hospitals when occupancy justifies activation.
- The company is considering acquiring land in multiple locations for sequential hospital commissioning.
2 more points from GPT Healthcare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is GPT Healthcare raising money or cutting debt?
See what GPT Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is GPT Healthcare's order book?
2 more points from GPT Healthcare Ltd's call on order book
Create a free account to keep reading this call
GPT Healthcare Ltd — Quarterly revenue & net profit
GPT Healthcare Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 136 |
| Operating profit (EBITDA) | 27 |
| Operating margin | 19.8% |
| Profit before tax | 21 |
| Net profit (PAT) | 15 |
| EPS (₹) | 1.88 |
Source: GPT Healthcare Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹136 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Healthcare Services
Continue your research
What GPT Healthcare's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
GPT Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were GPT Healthcare Ltd Q2 FY27 results?
GPT Healthcare reported net profit of ₹15 Cr (+36.4% YoY) on revenue of ₹136 Cr (+14.3% YoY) in Q2 FY27.
What is GPT Healthcare Ltd share price analysis?
GPT Healthcare Ltd currently shows a below-average growth signal. The stock trades at a P/E of 22.6 with a market cap of ₹1,179 Cr. Investors should review the full earnings analysis for detailed insights.
Is GPT Healthcare Ltd planning capital expenditure?
GPT Healthcare is commissioning a new 155-bed tertiary care hospital in Jamshedpur expected to commence operations in March-April 2027.
Keep GPT Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
